These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12848314)

  • 1. Coagulation dysfunction in sepsis and multiple organ system failure.
    Nimah M; Brilli RJ
    Crit Care Clin; 2003 Jul; 19(3):441-58. PubMed ID: 12848314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuing challenges of sepsis research.
    Crowther MA; Marshall JC
    JAMA; 2001 Oct; 286(15):1894-6. PubMed ID: 11597294
    [No Abstract]   [Full Text] [Related]  

  • 3. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
    Warren BL; Eid A; Singer P; Pillay SS; Carl P; Novak I; Chalupa P; Atherstone A; Pénzes I; Kübler A; Knaub S; Keinecke HO; Heinrichs H; Schindel F; Juers M; Bone RC; Opal SM;
    JAMA; 2001 Oct; 286(15):1869-78. PubMed ID: 11597289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nexus between systemic inflammation and disordered coagulation in sepsis.
    Opal SM
    J Endotoxin Res; 2004; 10(2):125-9. PubMed ID: 15120004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
    Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
    Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is worsening multiple organ failure the cause of death in patients with severe sepsis?
    Vincent JL; Nelson DR; Williams MD
    Crit Care Med; 2011 May; 39(5):1050-5. PubMed ID: 21317650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C.
    Pastores SM; Papadopoulos E; van den Brink M; Alicea M; Halpern NA
    Bone Marrow Transplant; 2002 Jul; 30(2):131-4. PubMed ID: 12132053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
    Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
    Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
    Kleinpell R
    Crit Care Nurse; 2003 Jun; 23(3):16-29; quiz 67-8. PubMed ID: 12830777
    [No Abstract]   [Full Text] [Related]  

  • 10. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock.
    Gando S; Nanzaki S; Sasaki S; Aoi K; Kemmotsu O
    Crit Care Med; 1998 Dec; 26(12):2005-9. PubMed ID: 9875912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology.
    Vincent JL
    Crit Care; 2001; 5(2):S1-5. PubMed ID: 11379985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2011 Dec; 12(6):443-9. PubMed ID: 22185191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.
    Sajan I; Da-Silva SS; Dellinger RP
    J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock.
    Gullo A; Iscra F; Di Capua G; Berlot G; Lucangelo U; Peratoner A; Fasiolo S; Viviani M; Consales C; Zicari A
    Minerva Anestesiol; 2005 Dec; 71(12):785-801. PubMed ID: 16288186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human activated protein C in severe sepsis.
    Mann HJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S19-23. PubMed ID: 11885409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis.
    Wiedermann CJ; Kaneider NC
    Ann Med; 2004; 36(3):194-203. PubMed ID: 15181975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
    Sollet JP; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coagulation inhibitors in sepsis and disseminated intravascular coagulation.
    Lee WL; Downey GP
    Intensive Care Med; 2000 Nov; 26(11):1701-6. PubMed ID: 11193281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.